Search

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes. Current members of EHA's Executive Board

Read more

Board elections

All members* who have paid their annual fees, have the privilege to influence the composition of the EHA Board. We need your involvement in the selection of EHA’s governmental body.

Read more

Mentoring peer-peer networks – a recipe for success

Isabel Peset1 & Alba Maiques-Diaz2

1 Senior Scientist, Microscopy, Medicines Discovery Catapult, Manchester, UK;
2 Postdoctoral scientist, Biomedical Epigenomics group, IDIBAPS, Barcelona, Spain; YoungEHA committee member.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Abstract & Clinical Case Submission and Travel Grant

Submit your abstract here

Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…

Read more

EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe”

On September 15-17, 2022, the EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was successfully held at the Occidental Praha hotel in Prague, Czechia.

Read more

Abstract Submission & Travel Grant Application

Late Poster Submission is now closed.

Read more